Zevra has sold its US Food and Drug Administration (FDA) priority review voucher (PRV) for $150m to an undisclosed party. The US-based company received the PRV when its Niemann-Pick disease type C ...

A zebra longwing butterfly is native to North America, and one of the 324 species studied to understand population decline.

For Zevra Therapeutics, last year’s approval of the rare lysosomal storage disorder drug Miplyffa appears to be the gift that keeps on giving. After receiving a rare pediatric disease priority ...

CELEBRATION, Fla. (AP) — CELEBRATION, Fla. (AP) — Zevra Therapeutics, Inc. (ZVRA) on Tuesday reported a loss of $35.7 million in its fourth quarter. The Celebration, Florida-based company said it had ...

CELEBRATION, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living ...

So let's assess the underlying fundamentals over the last 5 years and see if they've moved in lock-step with shareholder returns. View our latest analysis for Zevra Therapeutics .

CELEBRATION, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living ...

Zevra Therapeutics, Inc. announced that it will receive a 2025 New Treatment Award for its product MIPLYFFA™ (arimoclomol) at the 21st Annual WORLDSymposium. Eight abstracts related to MIPLYFFA ...

On Feb. 27, 2025, Zevra entered into an asset purchase agreement for the sale of a Rare Pediatric Disease Priority Review Voucher (PRV), issued by the U.S. FDA upon the approval of MIPLYFFA, for $150 ...